Navitoclax (ABT-263)

製品コードS1001

Navitoclax (ABT-263)化学構造

分子量(MW):974.61

Navitoclax (ABT-263)は一種の有効なBcl-xL、Bcl-2とBcl-w阻害剤で、無細胞試験でKi値が0.5 nM及び0.5 nM以下、1nM及び1nM以下と1nM及び1nM以下にそれぞれ分かれることですが、Mcl-1、A1と結合する作用が少し弱いです。臨床2期。

サイズ 価格 在庫  
JPY 57595.20 あり
JPY 17278.56 あり
JPY 28797.60 あり
JPY 53275.56 あり
JPY 139668.35 あり

文献中の引用(37)

カスタマーフィードバック(13)

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

製品安全説明書

Bcl-2阻害剤の選択性比較

生物活性

製品説明 Navitoclax (ABT-263)は一種の有効なBcl-xL、Bcl-2とBcl-w阻害剤で、無細胞試験でKi値が0.5 nM及び0.5 nM以下、1nM及び1nM以下と1nM及び1nM以下にそれぞれ分かれることですが、Mcl-1、A1と結合する作用が少し弱いです。臨床2期。
ターゲット
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1] Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
体外試験

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NGnhZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEC2Olkh|ryP M{jUVXNCVkeHUh?=
MV-4-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXJTWM2OD1yLkCxOVg3KM7:TR?= NHXWRo1USU6JRWK=
NKM-1 M3HpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW4XHNEUUN3ME2wMlAyPjl7IN88US=> Mlj1V2FPT0WU
ML-2 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnQTWM2OD1yLkCxPVg{KM7:TR?= NIHYd|hUSU6JRWK=
BV-173 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vocGlEPTB;MD6wNlMyPCEQvF2= M4DHNnNCVkeHUh?=
RS4-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX0eldKSzVyPUCuNFI2QDdizszN NEDtUlRUSU6JRWK=
HL-60 M3z6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7jWY1SUUN3ME2wMlAzQTB6IN88US=> MoHWV2FPT0WU
KY821 NH\CUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzQe4RRUUN3ME2wMlAzQTd3IN88US=> MXvTRW5ITVJ?
ECC10 NGDiNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DKWWlEPTB;MD6wN|c6OiEQvF2= MkT5V2FPT0WU
NCI-H720 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C0R2lEPTB;MD6wOFAyOSEQvF2= NIPtdolUSU6JRWK=
QIMR-WIL NVjzOHVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnaNIhKSzVyPUCuNFQzQDdizszN NF7uVXVUSU6JRWK=
KG-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrxVVRYUUN3ME2wMlA1PDh4IN88US=> NIH5bVNUSU6JRWK=
TGW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMES2N|Mh|ryP MXnTRW5ITVJ?
ATN-1 NFH3ZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3DTWM2OD1yLkC0O|M{KM7:TR?= NWDpTYoxW0GQR1XS
RH-18 NV;QV4twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTGTWM2OD1yLkC2NFQ5KM7:TR?= MmnJV2FPT0WU
EW-18 NILBPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LLbmlEPTB;MD6wOlg1OSEQvF2= MX;TRW5ITVJ?
NB17 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLkTWM2OD1yLkC3NVI1KM7:TR?= NHftT21USU6JRWK=
SK-NEP-1 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn3TWM2OD1yLkC3NlE{KM7:TR?= NEfDZXlUSU6JRWK=
P12-ICHIKAWA NYm5W2N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEe3O|gh|ryP NGLNNlZUSU6JRWK=
KARPAS-45 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XoRmlEPTB;MD6wO|gyPSEQvF2= MoDMV2FPT0WU
EW-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjTTWM2OD1yLkC4NFU{KM7:TR?= NInjTmdUSU6JRWK=
NB13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfGcWs4UUN3ME2wMlA5OjB|IN88US=> MUjTRW5ITVJ?
NCI-H209 NUD4[3k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHvVlAyUUN3ME2wMlA5PzB2IN88US=> MUDTRW5ITVJ?
NCI-H1092 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TFXWlEPTB;MD6xNFI4PSEQvF2= MX7TRW5ITVJ?
NH-12 NXvtXXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj0UIVKSzVyPUCuNVA4PDRizszN MWfTRW5ITVJ?
697 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLmZmhDUUN3ME2wMlExQDN7IN88US=> Ml;uV2FPT0WU
KE-37 M2PJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HhcmlEPTB;MD6xNVM4KM7:TR?= M4O2[3NCVkeHUh?=
MOLT-4 M{XY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\De4VKSzVyPUCuNVUyPjlizszN NFjibY5USU6JRWK=
CHP-134 M4HsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULFT5UzUUN3ME2wMlE3OzB4IN88US=> MUfTRW5ITVJ?
D-283MED NHPHPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESxNGJKSzVyPUCuNVc3QDZizszN NH7K[GNUSU6JRWK=
LU-135 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TUT2lEPTB;MD6xPFU2OiEQvF2= MlXMV2FPT0WU
LU-134-A MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3HTWM2OD1yLkG4OlcyKM7:TR?= MV\TRW5ITVJ?
EM-2 NUntR|lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF35VGtKSzVyPUCuNVk6OThizszN M2T3dXNCVkeHUh?=
LU-139 NY\uNlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[1ZmVKSzVyPUCuNlA1QThizszN MoHnV2FPT0WU
ALL-PO NVPYb|B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX3PZJlUUN3ME2wMlIyQTh6IN88US=> NWfXb285W0GQR1XS
NB12 NHHsO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rhSWlEPTB;MD6yN|EyPSEQvF2= M3LTeXNCVkeHUh?=
KP-N-YN NUWwOYV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7NOIlqUUN3ME2wMlI{PTd|IN88US=> M1f1SHNCVkeHUh?=
BEN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvZTWM2OD1yLkKzPVY5KM7:TR?= MVHTRW5ITVJ?
HCC1569 NX;zdoZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fPXGlEPTB;MD6yOVExPiEQvF2= NUDGN|JqW0GQR1XS
HuO9 M{\0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj0TWM2OD1yLkK2O|E2KM7:TR?= NHHX[IRUSU6JRWK=
WM-115 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPidIpNUUN3ME2wMlI4PzN6IN88US=> M3W2eHNCVkeHUh?=
CCRF-CEM MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwM{O1Nlkh|ryP NV;4dJo6W0GQR1XS
IST-SL1 NXi1eVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTKNJJKSzVyPUCuN|U{PDNizszN NFzpSGdUSU6JRWK=
BE-13 NXizdm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwM{[0OVkh|ryP NF;uW|BUSU6JRWK=
COR-L88 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknxTWM2OD1yLkO2OVQh|ryP M3;qUnNCVkeHUh?=
DOHH-2 NUnkVJRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNEGwNlMh|ryP NH3tNIRUSU6JRWK=
A704 NIX4WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNEK2O{DPxE1? MnfjV2FPT0WU
KNS-81-FD M2X0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LWWmlEPTB;MD60OFAyPyEQvF2= MoP3V2FPT0WU
RPMI-8226 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KTmNZUUN3ME2wMlQ2PjV{IN88US=> NWXHc3pxW0GQR1XS
TGBC24TKB M{i4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PDU2lEPTB;MD60OVc4QCEQvF2= NFjhUG5USU6JRWK=
NCI-H1304 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwNE[xOVch|ryP NGXHV5JUSU6JRWK=
MOLT-13 NI\QV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDBdodNUUN3ME2wMlQ3PjF|IN88US=> NV76[ZBQW0GQR1XS
EW-22 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzuTWM2OD1yLkS2OlcyKM7:TR?= MmfPV2FPT0WU
MS-1 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TUNGlEPTB;MD60Olk{OyEQvF2= M4HuPHNCVkeHUh?=
RMG-I MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnMUlRKSzVyPUCuOFk1PjRizszN NHPO[YdUSU6JRWK=
NTERA-S-cl-D1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwNUCwNVkh|ryP Ml22V2FPT0WU
NCI-H1048 NU\ycWlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X4UmlEPTB;MD61NFk2OyEQvF2= MVPTRW5ITVJ?
SW1417 M3:wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwNUW0N|gh|ryP MkHTV2FPT0WU
DB M3XESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Xxc2lEPTB;MD61O|A5KM7:TR?= NYHjUYhuW0GQR1XS
MEG-01 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWzNZBqUUN3ME2wMlU5OzJizszN M2nqZnNCVkeHUh?=
EW-13 NI\hdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwNUizOFEh|ryP M1v2UHNCVkeHUh?=
LAMA-84 NIX5WoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXj[HV5UUN3ME2wMlU6OjB5IN88US=> M13SNnNCVkeHUh?=
J-RT3-T3-5 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3IRoRpUUN3ME2wMlYxQDB6IN88US=> NYnaeZhXW0GQR1XS
MOLT-16 NXHobXNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrIdWRKSzVyPUCuOlUzPjRizszN NXW1OYtxW0GQR1XS
DU-4475 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV62S5FUUUN3ME2wMlY2PDJ5IN88US=> MV3TRW5ITVJ?
HAL-01 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDiTWM2OD1yLkeyOVQ6KM7:TR?= M13XZXNCVkeHUh?=
RD NELxcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fzemlEPTB;MD63OVg6QSEQvF2= MUPTRW5ITVJ?
OAW-28 NH3k[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\mTWM2OD1yLke4N|ch|ryP NUHxb4hHW0GQR1XS
HCC38 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDHeplKSzVyPUCuPFAyQSEQvF2= NYrT[VNVW0GQR1XS
NMC-G1 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwOEGxNlEh|ryP MnXYV2FPT0WU
EW-16 NHfEV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP3TWM2OD1yLkixN|I5KM7:TR?= M1LuRXNCVkeHUh?=
DU-145 M4OzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;KN2lEPTB;MD64PVkzOyEQvF2= MWLTRW5ITVJ?
HPAF-II M{LFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LUN2lEPTB;MD65NlYzQCEQvF2= Mk\qV2FPT0WU
A427 NHXsZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHhTWM2OD1yLkmzNFIzKM7:TR?= MXPTRW5ITVJ?
PA-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;jTWM2OD1yLkm1OlQzKM7:TR?= MVfTRW5ITVJ?
OAW-42 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z0eGlEPTB;MD65OlE1PiEQvF2= NU\L[5VtW0GQR1XS
L-428 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vEWGlEPTB;MT6wNVI2KM7:TR?= NVu1XZVnW0GQR1XS
COLO-824 NGfKTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[wTWM2OD1zLkCxO|A5KM7:TR?= NF\jTY1USU6JRWK=
P30-OHK NYjNbFh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwMES2PFgh|ryP Mm\VV2FPT0WU
NCI-H2170 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwME[yN{DPxE1? NYrTNnpPW0GQR1XS
HCC2998 NWDad2w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi5N|lKSzVyPUGuNFcyOzVizszN MVjTRW5ITVJ?
NB14 NUTYSolWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GzRmlEPTB;MT6xN|c1QCEQvF2= MXvTRW5ITVJ?
TGBC1TKB MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LmVWlEPTB;MT6xOFE2OiEQvF2= NGjpfXJUSU6JRWK=
KP-N-YS NIPWT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\pWZFKSzVyPUGuNVYzOzZizszN MYPTRW5ITVJ?
CAL-120 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPBO4FKSzVyPUGuNVY1OjlizszN MmLHV2FPT0WU
SBC-1 M1vkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTSdm9KSzVyPUGuNVkxPTNizszN Mkj3V2FPT0WU
C32 NWG1[HFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHuTWM2OD1zLkG5NFg5KM7:TR?= MkX4V2FPT0WU
HCC2157 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjofnZKSzVyPUGuNVk1QTRizszN NXzoXlZyW0GQR1XS
COLO-792 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD1zLkKwNFcyKM7:TR?= MVfTRW5ITVJ?
ES7 NX;KPIpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjoO2lQUUN3ME2xMlI4QTVzIN88US=> MYrTRW5ITVJ?
HEL MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwM{GwNlkh|ryP NVe1WGt1W0GQR1XS
ES4 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoCwTWM2OD1zLkO0PVk5KM7:TR?= MVXTRW5ITVJ?
NCI-SNU-1 M3Hyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mxOmlEPTB;MT6zOlU2PSEQvF2= Mlv3V2FPT0WU
MDA-MB-415 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OxV2lEPTB;MT6zPFg2KM7:TR?= NF22copUSU6JRWK=
NCI-H2342 NEDy[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;DS21KSzVyPUGuOFAzPjlizszN MmfiV2FPT0WU
NB69 M2DaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHXTWM2OD1zLkS2NlcyKM7:TR?= MkOxV2FPT0WU
D-247MG NWDnXJpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrhN|VKSzVyPUGuOVEyOjJizszN MUnTRW5ITVJ?
SCC-4 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwNUm4PFch|ryP NXzZXVRsW0GQR1XS
HuH-7 M3rGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\YNW9KSzVyPUGuOlczQTNizszN MofJV2FPT0WU
A388 M4PPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnhTWM2OD1zLk[4O|I1KM7:TR?= MmLNV2FPT0WU
Calu-3 M1n1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W4WGlEPTB;MT63NFY6PyEQvF2= M4G5dHNCVkeHUh?=
NCI-H1648 NFTIUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXFWmRKSzVyPUGuO|E1OThizszN MWfTRW5ITVJ?
NCI-H2052 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofOTWM2OD1zLkeyNlAyKM7:TR?= NHjC[VFUSU6JRWK=
Ramos-2G6-4C10 NHnPT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInIfHFKSzVyPUGuO|M3PTZizszN Mon5V2FPT0WU
DEL M1Hkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwN{S2PVIh|ryP MV3TRW5ITVJ?
SNU-423 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:2UZNpUUN3ME2xMlc5OTV5IN88US=> NHjBNHZUSU6JRWK=
COR-L23 M2[xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXtSolKSzVyPUGuO|k5PzRizszN Mk\1V2FPT0WU
OMC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\LUmdVUUN3ME2xMlg3ODF4IN88US=> MUfTRW5ITVJ?
EW-11 M37hbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;IXWxqUUN3ME2xMlk2PjV5IN88US=> NVXHeZF1W0GQR1XS
HSC-3 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXvVFhKSzVyPUGuPVY{PjVizszN NFSye2JUSU6JRWK=
MLMA NVTvTmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW5V|ZKSzVyPUGuPVY3PzdizszN Mn;JV2FPT0WU
RCM-1 M1\2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrD[5NKSzVyPUKuNFA{QTlizszN NFjVPWxUSU6JRWK=
MFE-280 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn5bodKSzVyPUKuNFI5PDhizszN M3jSSnNCVkeHUh?=
ES8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwMkW0O|Eh|ryP Mnf4V2FPT0WU
TE-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwMkm0O|Mh|ryP MWDTRW5ITVJ?
HuO-3N1 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTMSGlKSzVyPUKuOFg4QCEQvF2= Mkj2V2FPT0WU
MHH-NB-11 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNNWlEPTB;Mj61NVE2QCEQvF2= NYmzXXhSW0GQR1XS
TGBC11TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG1PGJKSzVyPUKuOVc3QDFizszN MmDSV2FPT0WU
HOP-92 NF7CNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jDT2lEPTB;Mj61PFc1OyEQvF2= MlTlV2FPT0WU
IGR-1 M1PxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwNkKwN|Uh|ryP M2m5[3NCVkeHUh?=
GOTO NFTOWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nncGlEPTB;Mj62OVM4PyEQvF2= M4\wWHNCVkeHUh?=
NCI-H1650 NXHuUY9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HCNWlEPTB;Mj63NlIyPSEQvF2= MmnXV2FPT0WU
NCI-H1581 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPJ[I5KSzVyPUKuO|k3QDFizszN M1\zb3NCVkeHUh?=
NCI-H2405 M2ryZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6zXYlKSzVyPUKuPFI4QDJizszN NV3UOWVPW0GQR1XS
U-118-MG MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfwTWM2OD1{Lkm2OFkyKM7:TR?= MlTsV2FPT0WU
DoTc2-4510 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3yVJVoUUN3ME2zMlAyPDF5IN88US=> NE[yUpNUSU6JRWK=
NCI-H596 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNwMES5PVch|ryP M3;TTHNCVkeHUh?=
MPP-89 M4XNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP3R2xJUUN3ME2zMlA2PjZ4IN88US=> NYPh[pQ4W0GQR1XS
GCIY MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DwVGlEPTB;Mz6yNFQ6OSEQvF2= MWXTRW5ITVJ?
SW626 MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwMkS1OFMh|ryP MU\TRW5ITVJ?
OCI-AML2 NIryVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX5b5dYUUN3ME2zMlMyOjd{IN88US=> NEixcGRUSU6JRWK=
NBsusSR MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojNTWM2OD1|LkO0PVM5KM7:TR?= M3SwOXNCVkeHUh?=
AN3-CA M4LwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmyTWM2OD1|LkS0NlM5KM7:TR?= M3Pm[nNCVkeHUh?=
EFM-19 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofYTWM2OD1|LkS4N|M6KM7:TR?= NFny[GlUSU6JRWK=
RVH-421 M1njd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrSTWM2OD1|LkW2PFc4KM7:TR?= NYjUbWt2W0GQR1XS
5637 NF;ubHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwNkGxNFMh|ryP NHnQNYNUSU6JRWK=
PANC-08-13 NIWzSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknhTWM2OD1|Lk[zOFczKM7:TR?= NFPwVpdUSU6JRWK=
H9 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ey[GlEPTB;Mz62O|E1PCEQvF2= MnLwV2FPT0WU
KARPAS-299 NXHVZoNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNwNkezOlEh|ryP MXjTRW5ITVJ?
TE-5 M{i0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTDVXRFUUN3ME2zMlcxPzB7IN88US=> NFfNWmxUSU6JRWK=
NOS-1 NU\pe3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwN{m4N|Qh|ryP MXjTRW5ITVJ?
HH NV36d29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnVZWFVUUN3ME2zMlg{QDZ6IN88US=> Ml\GV2FPT0WU
769-P NYDZNmlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fC[WlEPTB;Mz64PVUyKM7:TR?= NEPjT4dUSU6JRWK=
CHP-212 NIHjNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;peIQ4UUN3ME2zMlkzPTR7IN88US=> MnHMV2FPT0WU
NCI-H82 M1r3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTBeXN2UUN3ME2zMlk2QTN4IN88US=> M2TER3NCVkeHUh?=
Mo-T NV\TPIFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXHTWM2OD12LkC0N|EzKM7:TR?= MnjyV2FPT0WU
BB65-RCC NX7a[2FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\XWnBKSzVyPUSuNFQ{QTlizszN M4PZWXNCVkeHUh?=
SW1990 M2LS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr4TWM2OD12LkC1PVA5KM7:TR?= NYfWcFBtW0GQR1XS
LK-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TZPWlEPTB;ND6xNVI6OyEQvF2= NHPEVFNUSU6JRWK=
ES5 M1yyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLDRm9KSzVyPUSuNVM6QDVizszN NILLfIZUSU6JRWK=
JVM-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnZbVg2UUN3ME20MlE5OjJ{IN88US=> M1HCZXNCVkeHUh?=
RPMI-7951 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDHcJZiUUN3ME20MlIzPDF|IN88US=> NIfMb2tUSU6JRWK=
Calu-6 NHHhdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXhT4tKSzVyPUSuNlc5QDFizszN NHToNohUSU6JRWK=
LC-2-ad NIfBOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor1TWM2OD12LkK5OVY5KM7:TR?= M3yzN3NCVkeHUh?=
SW954 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwMkm2OkDPxE1? M2\lUXNCVkeHUh?=
H-EMC-SS NFvFUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nsR2lEPTB;ND6zNVg{OSEQvF2= M4jkT3NCVkeHUh?=
ES3 M3XufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLYTWM2OD12LkO1OFQyKM7:TR?= M17l[3NCVkeHUh?=
no-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRwM{W1OVQh|ryP NX;i[XdvW0GQR1XS
LAN-6 M2rOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vCZWlEPTB;ND60OVE5QSEQvF2= NYDJWW8{W0GQR1XS
FTC-133 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECy[4tKSzVyPUSuOVM6PSEQvF2= MYTTRW5ITVJ?
8505C Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PJXGlEPTB;ND61OFI{KM7:TR?= MoC4V2FPT0WU
SW620 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFywRplKSzVyPUSuOVcxPTdizszN NFrxUndUSU6JRWK=
BCPAP M{LSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3kSYNKSzVyPUSuOlM1QDFizszN MUPTRW5ITVJ?
SK-LU-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PCdmlEPTB;ND62OlA5QSEQvF2= MmXnV2FPT0WU
NCI-H1623 M2nWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHhTWM2OD12LkewNlI5KM7:TR?= M1nh[3NCVkeHUh?=
C2BBe1 M{H5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRwN{SwNFgh|ryP MXnTRW5ITVJ?
GP5d MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTRwN{izPFgh|ryP NGPON|hUSU6JRWK=
NB6 NWjnNlNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnviTWM2OD12Lki2NlA1KM7:TR?= M2nYVHNCVkeHUh?=
MDA-MB-157 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTRwOEi3OkDPxE1? NX;zN3N1W0GQR1XS
UMC-11 NWr1W2kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWyTWM2OD12Lki4PVY1KM7:TR?= NEH5RVlUSU6JRWK=
HCC1419 NFLwPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m3UGlEPTB;ND65NFA3OyEQvF2= MYTTRW5ITVJ?
NCI-H2029 NIf1VXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPMdJlxUUN3ME20Mlk1OTh3IN88US=> NXLaWYo1W0GQR1XS
LXF-289 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTVwMEO3NVkh|ryP MX\TRW5ITVJ?
KINGS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfITWM2OD13LkC3O|Q1KM7:TR?= MknMV2FPT0WU
HD-MY-Z NYLWV4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\1SotJUUN3ME21MlI{QTZ7IN88US=> NFjqcGxUSU6JRWK=
ESS-1 NX\mPGhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTVwMkW1PVch|ryP Mnz1V2FPT0WU
GI-1 NHfOPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nDdmlEPTB;NT6yO|kzPiEQvF2= Mn7SV2FPT0WU
RPMI-2650 NFjJSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTVwM{[xOkDPxE1? NFnySHJUSU6JRWK=
IA-LM MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e1TGlEPTB;NT6zPVg4OSEQvF2= M{nTZ3NCVkeHUh?=
KP-4 NFTkcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwNE[zN|Qh|ryP NX\1VndiW0GQR1XS
G-402 NIfxS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yyUGlEPTB;NT61NVg3PSEQvF2= M3y0SXNCVkeHUh?=
OS-RC-2 MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXyb|ZUUUN3ME21MlUzPjB2IN88US=> NX\ZSIs3W0GQR1XS
NCI-H1155 M1fGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe4Z5RKSzVyPUWuOVQ6PTVizszN MlPWV2FPT0WU
OE19 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTVwNki2NlQh|ryP NWXYPZNTW0GQR1XS
U-2-OS M{\UZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL6dYNbUUN3ME21Mlg6ODF|IN88US=> M4nsRXNCVkeHUh?=
SCC-15 NFryPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPweVRKSzVyPUWuPVM3PjJizszN NGPSOpdUSU6JRWK=
NCI-H630 M{jPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG4e|FKSzVyPUWuPVk1ODRizszN NYD5eZE1W0GQR1XS
PFSK-1 M1;IV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLaTWM2OD14LkC1NlU6KM7:TR?= NHHmbZZUSU6JRWK=
NCI-H1770 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTZwMkC4O|Qh|ryP NV\HdVZPW0GQR1XS
SK-MEL-3 NVH4dIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PRVWlEPTB;Nj60NlkyPSEQvF2= MW\TRW5ITVJ?
LB1047-RCC MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3PdJVKSzVyPU[uOFc3OjVizszN NWPGe5p2W0GQR1XS
NCI-H446 NUTubIpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:wOFNKSzVyPU[uOlI6OjVizszN MV\TRW5ITVJ?
SW780 NVewN5JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v2S2lEPTB;Nj63NFE5PSEQvF2= MULTRW5ITVJ?
NEC8 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTZwN{[2N{DPxE1? NYLwdG5WW0GQR1XS
NOMO-1 NVjkZ5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3STWM2OD14Lke4NVEyKM7:TR?= NHf3emJUSU6JRWK=
COLO-668 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;z[Hd5UUN3ME22Mlg1Ozh5IN88US=> M{nDOHNCVkeHUh?=
MC116 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHBd3ZuUUN3ME22Mlk{QDl5IN88US=> M4nvWnNCVkeHUh?=
HCC1937 M4fPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPtTVNKSzVyPU[uPVkzPTFizszN M163eHNCVkeHUh?=
NCI-N87 NWPFTYZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f2NWlEPTB;Nz6xPVI6OyEQvF2= M4foW3NCVkeHUh?=
COLO-320-HSR NHS1W|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTdwMkK3N|gh|ryP Mmq5V2FPT0WU
HCC1806 M1rocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nuc2lEPTB;Nz6yOlA1PCEQvF2= NHHJUJBUSU6JRWK=
OVCAR-3 NWHhcYpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\NRoJqUUN3ME23MlM{ODN6IN88US=> MoTVV2FPT0WU
NUGC-3 M13nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D6dGlEPTB;Nz6zPVY6PCEQvF2= MmDvV2FPT0WU
SW1783 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHxWG1KSzVyPUeuOFMyPzVizszN MmPlV2FPT0WU
GCT M2\vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z4TWlEPTB;Nz61OlkxPiEQvF2= M1TGdHNCVkeHUh?=
NCI-H2126 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XzSmlEPTB;Nz63N|YzPSEQvF2= NGnDNHhUSU6JRWK=
MEL-HO Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTdwN{ewOVQh|ryP NHPITHdUSU6JRWK=
CAPAN-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTdwN{ezOVch|ryP NXT6O2lFW0GQR1XS
SW756 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nnWWlEPTB;Nz63PFM{OyEQvF2= NYrYT|lDW0GQR1XS
SKG-IIIa MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XXS2lEPTB;Nz64NVg6OiEQvF2= MXTTRW5ITVJ?
HCE-T NVXuVHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnZeW1wUUN3ME23Mlg4Pzh|IN88US=> MVjTRW5ITVJ?
Ca-Ski M37FO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHsdllKSzVyPUeuPVk{QDNizszN MkXOV2FPT0WU
COLO-684 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRThwMEG4NVgh|ryP MYLTRW5ITVJ?
KYSE-70 NH;iPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRThwMEe3Nlkh|ryP M{\jO3NCVkeHUh?=
TI-73 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj1XmhKSzVyPUiuNlU5PTFizszN NWPqPZJIW0GQR1XS
BT-20 NIH2TIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX1b2VKSzVyPUiuNlYxPTJizszN NHi5OmZUSU6JRWK=
MHH-ES-1 NH\3TItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml70TWM2OD16LkWxPFM1KM7:TR?= MV\TRW5ITVJ?
TE-12 NUXZUmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjUT2tKSzVyPUiuOVk6OzFizszN M1vwSHNCVkeHUh?=
YH-13 NGOzN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33MOGlEPTB;OD62NVAxQCEQvF2= MXvTRW5ITVJ?
SF126 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PXeWlEPTB;OD64N|g3PSEQvF2= NUDacIc{W0GQR1XS
J82 M{PXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRThwOUCwN|gh|ryP NH\ES4VUSU6JRWK=
RCC10RGB NUPDbI15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRThwOUm1OlEh|ryP Ml[yV2FPT0WU
SK-UT-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nJVmlEPTB;OT6wOFk1PSEQvF2= M3PXXnNCVkeHUh?=
LB2241-RCC M3HjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTlwMUmxN|ch|ryP NX65Xo5JW0GQR1XS
LB996-RCC M4j0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXGOZdUUUN3ME25MlE6QDlizszN NIXES5lUSU6JRWK=
EPLC-272H NHGyU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPYTlBKSzVyPUmuN|c3PTdizszN M4ns[XNCVkeHUh?=
CTV-1 NYDNUnB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XvXGlEPTB;OT61OlU{OiEQvF2= M4DTU3NCVkeHUh?=
HSC-2 NW\4bGQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHSTWM2OD17LkW3OVUh|ryP MlixV2FPT0WU
SK-MEL-28 NICwbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvVXldUUUN3ME25MlYyQDl|IN88US=> M{W2bnNCVkeHUh?=
MMAC-SF MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT0PIJKSzVyPUmuOlg4PSEQvF2= MmLSV2FPT0WU
CP50-MEL-B Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTlwN{W3PFIh|ryP M2LLbnNCVkeHUh?=
HT-1080 NUiwcI1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTlwN{e3N|kh|ryP NVTUNZZTW0GQR1XS
HEC-1 NXvOTJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrqTWM2OD1zMD6zN|UzKM7:TR?= M2ryV3NCVkeHUh?=
AGS M3[5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFyLkO3OEDPxE1? MVPTRW5ITVJ?
GAMG Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\UdHh3UUN3ME2xNE42OTZ{IN88US=> NVvEPXhCW0GQR1XS
SW48 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q5WmlEPTB;MUCuOVE5QSEQvF2= M1PW[3NCVkeHUh?=
U031 NIfwUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHhfoNKSzVyPUGwMlU6ODhizszN M1G1eHNCVkeHUh?=
OVCAR-5 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHlOFFKSzVyPUGwMlY1OjlizszN MVrTRW5ITVJ?
SF295 NXrWbmZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HLSGlEPTB;MUCuOlcxPCEQvF2= M1PtO3NCVkeHUh?=
BHT-101 NHW5ZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LRZmlEPTB;MUCuO|E4PyEQvF2= NEfwdXVUSU6JRWK=
VMRC-RCZ MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlexTWM2OD1zMT6zNlAyKM7:TR?= MlnuV2FPT0WU
ACHN NG\se5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jzc2lEPTB;MUGuOFIyOSEQvF2= MoLtV2FPT0WU
NCI-H526 NXftTWpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37kSmlEPTB;MUGuOVA1OyEQvF2= NEKxdJBUSU6JRWK=
MN-60 NXi3U3VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj3XmtpUUN3ME2xNU42OzlizszN NVTxN2hMW0GQR1XS
NCI-H2291 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFzLkW0OlYh|ryP M3PBWHNCVkeHUh?=
SCC-25 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jFR2lEPTB;MUGuO|U2PiEQvF2= NEO1PVZUSU6JRWK=
SK-MEL-2 NEj2cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T3VWlEPTB;MUGuO|Y{PyEQvF2= MYDTRW5ITVJ?
SN12C NXi2UG57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkmzOVUh|ryP M2jGbXNCVkeHUh?=
NCI-H69 M2[wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP1TWM2OD1zMj60NlM1KM7:TR?= NX7lNplvW0GQR1XS
ME-180 M2PQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnSTWM2OD1zMj63NFU1KM7:TR?= MXHTRW5ITVJ?
MC-IXC MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M335WmlEPTB;MUKuO|UyQCEQvF2= M3vZZXNCVkeHUh?=
NCI-H2347 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XDZWlEPTB;MUKuO|YyPCEQvF2= MYHTRW5ITVJ?
M059J MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHezUIxKSzVyPUGyMlc4OjdizszN NEHXT4ZUSU6JRWK=
A2058 NWnsVIlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL2ZnFKSzVyPUGyMlg3QDFizszN NH;tTFFUSU6JRWK=
VA-ES-BJ MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF{Lki3PFUh|ryP NYezUZpVW0GQR1XS
Ca9-22 MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTKTWM2OD1zMj65OFUyKM7:TR?= NU\MWoRlW0GQR1XS
KNS-42 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXnTWM2OD1zMj65PVg1KM7:TR?= MkTSV2FPT0WU
LoVo NF7ZXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5TWM2OD1zMz6yN|E{KM7:TR?= MnzKV2FPT0WU
AM-38 NH64RlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DzTWlEPTB;MUOuNlU3PiEQvF2= M2HNcXNCVkeHUh?=
NB5 NY\sTmlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrNR2h5UUN3ME2xN{4{PzV{IN88US=> MoDJV2FPT0WU
L-363 NX7jZZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF|LkSwN|Mh|ryP MlTtV2FPT0WU
SK-MEL-30 M4POZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF2LkC2OFUh|ryP NFHCfXpUSU6JRWK=
NCI-H1563 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXySlVKSzVyPUG0MlYxOzlizszN M1\VdnNCVkeHUh?=
NCI-H2228 NUHLfWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF2Lk[wO|ch|ryP MnLUV2FPT0WU
MFM-223 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF3LkG4NVMh|ryP M2PFTnNCVkeHUh?=
LB831-BLC NX\C[VVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TWZmlEPTB;MUWuNlc3PyEQvF2= MYrTRW5ITVJ?
SW872 NHi2OFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL0flZrUUN3ME2xOU4{ODh4IN88US=> MkSzV2FPT0WU
NCI-H522 M13YVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHWW2tYUUN3ME2xOU4{OzB4IN88US=> M4K1d3NCVkeHUh?=
EW-1 M2rpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF3LkW0OlIh|ryP NWXGdJdvW0GQR1XS
HN M3\KNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXzZY5KSzVyPUG1MlU6PDJizszN MYnTRW5ITVJ?
SW837 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF3Lke4OFch|ryP M1TjW3NCVkeHUh?=
SCC-9 NIq2WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWz[2tKSzVyPUG1MlgyOTRizszN NIHuXFdUSU6JRWK=
MKN7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\aPIhKSzVyPUG1Mlk4OzJizszN NFS0V5hUSU6JRWK=
KYSE-410 NWHIN5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;HS2dPUUN3ME2xOk42QTFizszN NEXEbGtUSU6JRWK=
SK-N-DZ NIe5bmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfHO4pKSzVyPUG2MlYyOTZizszN NW\KbWROW0GQR1XS
COR-L105 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF4Lk[1Nlgh|ryP M3fBd3NCVkeHUh?=
LB2518-MEL M3PqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\DdIw2UUN3ME2xOk45Ozh7IN88US=> NVrFT5A{W0GQR1XS
OVCAR-4 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7teVJJUUN3ME2xOk45QDZ{IN88US=> NXTQd49WW0GQR1XS
TK10 NUG2UWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17hNmlEPTB;MU[uPVQ4OyEQvF2= NXvWdIkxW0GQR1XS
KNS-62 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm2[VdvUUN3ME2xOk46Pzd5IN88US=> NU\0eHg2W0GQR1XS
RPMI-8866 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWryNG1SUUN3ME2xO{4yPzN{IN88US=> Moi3V2FPT0WU
HuP-T4 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF5LkK0PVUh|ryP NEDFOZVUSU6JRWK=
CGTH-W-1 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzMdINtUUN3ME2xO{42OjF7IN88US=> MWrTRW5ITVJ?
T-24 M{Pr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF5LkWzOFch|ryP MX\TRW5ITVJ?
HT-3 M1KxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW5OGJKSzVyPUG3MlU6OTRizszN NXP2e5V6W0GQR1XS
KS-1 M4HFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PBPGlEPTB;MUeuOlc{KM7:TR?= M3nGfnNCVkeHUh?=
NCI-H1792 NEnSXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLpTWM2OD1zNz63PVgh|ryP MWDTRW5ITVJ?
ABC-1 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF5LkixOFEh|ryP MnW2V2FPT0WU
BPH-1 NUHnPWJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF6LkG2PFUh|ryP M{jRfXNCVkeHUh?=
A431 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nF[GlEPTB;MUiuOFEzPyEQvF2= MmLTV2FPT0WU
T98G NYqyd5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF6LkWxOVch|ryP MlO1V2FPT0WU
BHY MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TUOmlEPTB;MUiuPFY6KM7:TR?= MlrsV2FPT0WU
Capan-2 M2OwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rXV2lEPTB;MUiuPVA4QCEQvF2= NHvBd|JUSU6JRWK=
MDA-MB-175-VII M1XWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLFTWM2OD1zOD65NlA6KM7:TR?= NELKToJUSU6JRWK=
CAL-27 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljyTWM2OD1zOT6wOFg4KM7:TR?= NEKyOIVUSU6JRWK=
AsPC-1 NXfDPHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;LZ25KSzVyPUG5Mlg3PTdizszN M3fPT3NCVkeHUh?=
KU812 M3[xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH6Z2ZKSzVyPUG5Mlk2PzNizszN MYLTRW5ITVJ?
NCI-H441 NF3CSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInhZoxKSzVyPUKwMlAxOSEQvF2= MWfTRW5ITVJ?
Mewo MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjlT5JiUUN3ME2yNE4yOjh6IN88US=> MYrTRW5ITVJ?
SK-MEL-24 NV3VRYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rNZmlEPTB;MkCuNVQ4PyEQvF2= Mor6V2FPT0WU
NCI-H727 M3jVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX1doV5UUN3ME2yNE4zPzB2IN88US=> MlLDV2FPT0WU
EKVX NYfRcZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHhZWwyUUN3ME2yNE43ODZizszN NXO3XoVwW0GQR1XS
RT-112 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjQN|FKSzVyPUKwMlYyOjJizszN MlLCV2FPT0WU
CAMA-1 NW\yO5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\iVmFKSzVyPUKwMlk5ODNizszN MVPTRW5ITVJ?
SW900 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnZdGM5UUN3ME2yNU4xOTR7IN88US=> MUTTRW5ITVJ?
NCI-H23 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXNTWM2OD1{MT6xNlc4KM7:TR?= MUTTRW5ITVJ?
SK-PN-DW MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELkXFdKSzVyPUKxMlE3PDlizszN NHf3U2RUSU6JRWK=
BB30-HNC NX;CNmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf5XVJsUUN3ME2yNU4zPzR3IN88US=> NHrTXolUSU6JRWK=
VM-CUB-1 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfvbnlFUUN3ME2yNU4{PTN4IN88US=> NEPj[3lUSU6JRWK=
IST-MEL1 NW\XPFRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInXdnpKSzVyPUKxMlM3QTJizszN M37Wc3NCVkeHUh?=
CTB-1 NGfGN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XqV2lEPTB;MkGuOFc2PSEQvF2= MnSyV2FPT0WU
LCLC-103H MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ{LkG1PFIh|ryP MornV2FPT0WU
PANC-03-27 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ{LkWxOlkh|ryP MnP5V2FPT0WU
HTC-C3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7NcYxKSzVyPUKyMlU2PTVizszN M1uyVHNCVkeHUh?=
TE-8 NGHqXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj5U5JCUUN3ME2yN{4zPTZ3IN88US=> NHTXdmhUSU6JRWK=
NCI-H292 M1rBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfkV4Y1UUN3ME2yOU4{PTN4IN88US=> MYrTRW5ITVJ?
COLO-680N MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ3Lk[zNlkh|ryP MnrhV2FPT0WU
KYSE-520 NVju[JM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17qdmlEPTB;MkWuOlQ1KM7:TR?= MYnTRW5ITVJ?
NB10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXryVol5UUN3ME2yOk4{OTF5IN88US=> MXHTRW5ITVJ?
NCI-H661 NIDGZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLXTWM2OD1{Nj60O|E{KM7:TR?= MXrTRW5ITVJ?
GMS-10 NV7D[oU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfnOZhKSzVyPUK2Mlg3OzhizszN MlnsV2FPT0WU
NCI-H2122 NUjzU5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfUTWM2OD1{Nj65PVk5KM7:TR?= M1rES3NCVkeHUh?=
OVCAR-8 NH[wOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm3TVVrUUN3ME2yO{4xPjN6IN88US=> M{jhTXNCVkeHUh?=
DJM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfCe|BsUUN3ME2yO{4yPDV2IN88US=> M17JZ3NCVkeHUh?=
UACC-893 MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrtSVhKSzVyPUK3Mlk5PzhizszN M1HtO3NCVkeHUh?=
C8166 NUTGVYRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\G[pZQUUN3ME2yPE43QTN6IN88US=> M{[4b3NCVkeHUh?=
NCI-H1693 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki0TWM2OD1{OD62PVc2KM7:TR?= NHXG[lhUSU6JRWK=
TYK-nu NGTCNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;4T3VKSzVyPUOwMlA{PDVizszN MnHFV2FPT0WU
SW1710 NVPtOGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rTVWlEPTB;M{CuNVI3KM7:TR?= MojnV2FPT0WU
A375 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\odGlEPTB;M{CuN|I1OyEQvF2= NV30VW45W0GQR1XS
HMV-II MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDDXYZ2UUN3ME2zNU4{PTl{IN88US=> MV3TRW5ITVJ?
NCI-H2087 NGq1SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNzLk[zOVIh|ryP NH3M[mZUSU6JRWK=
CAL-54 NYDWV4xIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHjbYpzUUN3ME2zNU44OjRzIN88US=> NHTwVmlUSU6JRWK=
HCC70 M2Prc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;DWmlEPTB;M{KuNVM5PyEQvF2= M4X3OnNCVkeHUh?=
ES1 M1fwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[5SXFlUUN3ME2zNk4{ODZ{IN88US=> M4Xs[3NCVkeHUh?=
NCI-H1355 M{K4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n6OGlEPTB;M{OuNlA1KM7:TR?= M{PPW3NCVkeHUh?=
CFPAC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN|LkKzN|Ih|ryP NGPSTG9USU6JRWK=
MKN28 NVnjN4l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TNGlEPTB;M{OuN|gxQSEQvF2= Mkj1V2FPT0WU
HDLM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfBS2NKSzVyPUOzMlY6OzFizszN NELIfGRUSU6JRWK=
PANC-10-05 NGD1bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7lepVKSzVyPUO0MlExOTRizszN MXfTRW5ITVJ?
SAS NFTLWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:1coNHUUN3ME2zOE41PTZ3IN88US=> MV\TRW5ITVJ?
HCC1395 NIHrRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe4ZWcxUUN3ME2zOE44OTh4IN88US=> MUXTRW5ITVJ?
8305C MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vkPGlEPTB;M{WuPFQyPSEQvF2= MoP1V2FPT0WU
KM12 NUn6U485T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jSd2lEPTB;M{[uO|U1PyEQvF2= NUXiZnlpW0GQR1XS
SW1116 NYDtT25xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN5LkW5PVIh|ryP M4\2eHNCVkeHUh?=
SK-MEL-1 NVHVO|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvXTWM2OD1|OD6zN|g6KM7:TR?= NVK0XJY4W0GQR1XS
HCC2218 NFHrUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zRdmlEPTB;M{iuOlUyQSEQvF2= MVHTRW5ITVJ?
T84 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPzTWM2OD1|OD63OFA6KM7:TR?= MYTTRW5ITVJ?
ETK-1 NITmb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofHTWM2OD1|OT6wNlIh|ryP M1TNWHNCVkeHUh?=
COLO-800 NUfkOGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHjbm9KSzVyPUO5MlM5PjhizszN NGjJcI9USU6JRWK=
CAL-12T NEDWO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzvTWM2OD1|OT61NlgyKM7:TR?= NHz1VoVUSU6JRWK=
ACN NEPpV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHjO2dKSzVyPUSwMlQ6OTFizszN NIr3PGdUSU6JRWK=
SJSA-1 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDX[GNCUUN3ME20NU4yPTl4IN88US=> MV3TRW5ITVJ?
PSN1 NVPrOWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnZSmtKSzVyPUSxMlE4PDlizszN Mn2yV2FPT0WU
D-566MG M3HWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfjeWM5UUN3ME20NU4zODh4IN88US=> NVHF[pVuW0GQR1XS
EGI-1 NFrSO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTIbGVsUUN3ME20Nk41OjhizszN MYDTRW5ITVJ?
A204 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknQTWM2OD12Mj62N|g5KM7:TR?= NWTJeJVoW0GQR1XS
Saos-2 M4HTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\wV2lEPTB;NEKuPFM3QSEQvF2= MX7TRW5ITVJ?
SNU-C2B NVjTemVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LtSGlEPTB;NEOuOlg4QCEQvF2= MmD6V2FPT0WU
HLE MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTR2LkC4OVYh|ryP NFnJWYdUSU6JRWK=
SW1463 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR2Lkm5O|Eh|ryP M1vwPHNCVkeHUh?=
DSH1 NH3Ce2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILuTFhKSzVyPUS1MlAxOzNizszN NFrHWXRUSU6JRWK=
MCF7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHHPIFKSzVyPUS1MlUxPTFizszN M1;5T3NCVkeHUh?=
K5 NEnZZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnR[Y1FUUN3ME20OU46PDB3IN88US=> MU\TRW5ITVJ?
NCI-H358 NFjHO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR5LkKxOUDPxE1? NUCwfmpUW0GQR1XS
NCI-H2030 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXezS2FwUUN3ME20O{4zOzd2IN88US=> NIn4[IpUSU6JRWK=
SW948 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LMS2lEPTB;NEeuOFY1KM7:TR?= M3zxcnNCVkeHUh?=
BALL-1 NIn1[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR5Lk[xOlgh|ryP NHS2bodUSU6JRWK=
TE-9 NV2xZ5pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR5Lkm1PFEh|ryP NGHMUVlUSU6JRWK=
SK-N-FI NGXnSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTR6LkCzOVgh|ryP NXT0eXY2W0GQR1XS
KALS-1 NVzYRpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnJSXFIUUN3ME20PE4yOjh7IN88US=> NF7FbI1USU6JRWK=
HO-1-N-1 NV7BNYV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W5V2lEPTB;NEiuO|Q1PSEQvF2= NWrvfVNwW0GQR1XS
NCI-H2452 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13hUGlEPTB;NEmuNVE2OiEQvF2= NYnmWXFIW0GQR1XS
OC-314 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\u[YM2UUN3ME20PU43QDN2IN88US=> MX;TRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
細胞試験:

[1]

+ 展開
  • 細胞株: SCLC cell lines
  • 濃度: 0-1 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: C.B.-17 scid-bg or C.B.-17 scid mice
  • 製剤: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • 投薬量: 100 mg/kg/d
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+corn oil
7mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • 回答:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • 問題2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • 回答:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2信号経路図

Bcl-2 Inhibitors with Unique Features

相関Bcl-2製品

Tags: Navitoclax (ABT-263)を買う | Navitoclax (ABT-263) ic50 | Navitoclax (ABT-263)供給者 | Navitoclax (ABT-263)を購入する | Navitoclax (ABT-263)費用 | Navitoclax (ABT-263)生産者 | オーダーNavitoclax (ABT-263) | Navitoclax (ABT-263)化学構造 | Navitoclax (ABT-263)分子量 | Navitoclax (ABT-263)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID